RMD|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $2.69 | - | - |
| Q4'26 | $2.92 | $2.95 | +1.1% |
| Q3'26 | $2.80 | $2.86 | +2.2% |
| Q3'25 | $2.50 | $2.55 | +2.1% |
| Q2'25 | $2.48 | $2.55 | +2.8% |
| Q1'25 | $2.36 | $2.37 | +0.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $1.5B | - | - |
| Q4'26 | $1.5B | $1.5B | -0.7% |
| Q3'26 | $1.4B | $1.4B | +0.6% |
| Q3'25 | - | $1.3B | - |
| Q2'25 | - | $1.3B | - |
| Q1'25 | - | $1.3B | - |
Market Data
RMD Stock Snapshot
RMD is currently trading at $220.05, giving ResMed Inc. a market cap of 30.74B and a P/E ratio of 20.2. Today's range spans $210.58–$220.41, with shares opening at $211.89 and moving down $0.05 (0.0%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 50/100.
Over the past year RMD has traded between $180.26 and $293.81 - the current price is +22.1% off the 52-week low and -25.1% from the high.
Short interest data on large-cap Healthcare names like RMD (30.74B market cap) becomes relevant when the technical picture turns bullish - a BUY on 68/100 with neutral sentiment (50/100) is exactly the kind of setup that makes shorts nervous. Price at $220.05 (in the lower half of its 52-week range in $180.26–$293.81). The current P/E ratio stands at 20.2. Short covering in a bullish technical phase can add a secondary momentum layer on top of genuine long-side conviction - a dynamic worth monitoring in the current setup.
What makes RMD's BUY setup (68/100) particularly actionable at 30.74B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $220.05 (in the lower half of its 52-week range in $180.26–$293.81), with sentiment running neutral at 50/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: ResMed Inc. (RMD)
ResMed Inc. (RMD) reported Q3 2025 revenue of $1.335B and EPS of $2.55, exceeding analyst expectations of $1.335B and $2.49874. The company’s top‑line growth of 7.5% YoY underscores a robust demand for sleep‑apnea diagnostics. Cash‑flow generation remains strong, with operating cash flow consistently above $200M in the past four quarters. The firm’s capital return policy is anchored by a disciplined buyback program that averaged $1.2B in 2024 and $1.5B in 2025, reflecting a commitment to returning excess cash to shareholders. RMD’s dividend policy remains modest but stable, providing a predictable yield for income‑focused investors. Together, these metrics paint a picture of a company prioritizing cash‑flow durability over speculative growth.
At current price of $211.94, RMD sits 31.5% above its 52‑week low and 19.3% below its high of $293.81. The analyst consensus target of $248.33 suggests a potential upside of roughly 17% from today’s level, while the upper range of $325.00 indicates a broader valuation ceiling. RMD trades at a forward P/E of 20.23, comfortably below the peer average of 53.0, positioning it as a discount relative to peers such as AbbVie and Abbott Laboratories. The 1‑year return of –13.5% reflects a recent pullback, yet the 3‑month return of 2.4% signals a modest rebound in momentum. Sentiment has been rising over the past 14 days, with a score of 52, indicating improving market perception. These data points suggest that the stock is trading at a value that may still allow room for upside if cash‑flow stability is maintained.
ResMed’s AirView cloud platform now supports over 1.5 million patients worldwide, delivering real‑time monitoring and data analytics that drive higher adherence rates. The myAir app has expanded its user base by 25% YoY, enhancing patient engagement and reducing the need for in‑clinic visits. These digital solutions contribute to margin expansion, with the services segment reporting a 12% increase in operating margin in Q3 2025. The company’s focus on AI‑driven analytics positions it to capture additional revenue from predictive health management. By integrating hardware diagnostics with cloud analytics, ResMed reduces the total cost of care for payers, strengthening its competitive moat. The continued growth of the cloud portfolio is a key catalyst for future earnings resilience.
ResMed has delivered five consecutive earnings beats, with Q3 2026 EPS of $2.86 surpassing the $2.8 estimate. The company’s disciplined operating margin of 18% in Q4 2026 reflects efficient cost management amid expanding services. Capital allocation remains a priority, with a buyback program projected to exceed $2B this fiscal year, supported by robust free cash flow of $350M. Dividend payouts have increased by 4% annually, providing a modest yield that complements the buyback strategy. The combination of earnings consistency and a strong return policy mitigates downside risk and aligns shareholder interests. Investors can view RMD as a vehicle for steady capital appreciation in a sector with durable demand.
Recent analyst adjustments have kept RMD’s price target range tight, with RBC Capital maintaining a sector‑perform rating and a target of $244 while Jefferies, Mizuho, and Morgan Stanley trimmed their targets slightly amid concerns over a production glitch in Astral ventilators. The company’s market share in sleep‑apnea diagnostics remains above 30% in the U.S., and the divestiture of MatrixCare for $490M is expected to free capital for AI initiatives. Sentiment has risen to 52 over the past 14 days, indicating improving market perception as the ventilator issue is addressed. Regulatory scrutiny and supply‑chain constraints for ventilator components pose ongoing risks, but the firm’s cash‑flow durability and disciplined capital return policy provide a buffer. Overall, the outlook remains positive for investors seeking a defensible position in respiratory care.
Cash‑Flow Durability
Operating cash flow consistently exceeds $200M, enabling a robust buyback program and a stable dividend stream.
Free cash flow of $350M in Q4 2026 supports capital allocation without compromising growth investments.
The company’s cash‑flow generation outpaces industry peers, providing a cushion against market volatility.
Capital Return Policy
ResMed’s buyback program averaged $1.2B in 2024 and $1.5B in 2025, reflecting a disciplined return of excess capital.
Dividend payouts have risen by 4% annually, offering a modest yield that complements the buyback strategy.
The company’s return policy aligns shareholder interests with long‑term value creation, reducing dilution risk.
Cloud Services Growth
AirView now serves over 1.5 million patients globally, generating recurring revenue and improving adherence rates.
The myAir app’s 25% YoY user growth fuels higher engagement and reduces the need for in‑clinic visits.
Digital solutions contribute to a 12% increase in operating margin, expanding the company’s profit base.
Peer Valuation Edge
ResMed trades at a forward P/E of 20.23, well below the peer average of 53.0, positioning it as a discount relative to competitors.
The 20.23 P/E reflects strong earnings growth and a lower valuation multiple, offering upside potential within the sector.
Compared to peers like AbbVie and Abbott Laboratories, RMD’s valuation provides a margin of safety for risk‑averse investors.
Risk & Resilience
Production glitches in Astral ventilators and supply‑chain constraints pose short‑term operational risks that could impact FY27 guidance.
Regulatory scrutiny remains a factor, but the company’s robust compliance framework mitigates potential penalties.
Cash‑flow durability and a disciplined capital return program provide a buffer that protects shareholder value during market turbulence.
Positioning RMD
RMD shares are attractive when the price approaches the 52‑week low of $180.265, offering a 31.5% cushion from the current level. If the stock trades near the analyst consensus target of $248.33, the upside potential narrows to roughly 17%, suggesting a prudent pause in accumulation. A rise above the upper target of $325.00 would signal overvaluation and warrant a reduction in exposure. Monitor the company’s quarterly earnings for any sign of earnings beat erosion or a slowdown in cash‑flow generation, as these could justify a rebalancing. Position sizing should consider the firm’s beta of 0.8 and its strong cash‑flow durability, ensuring that the allocation aligns with the portfolio’s risk tolerance.
Risk Factors
ResMed’s risk profile blends product‑specific concerns, payer dynamics, and market sentiment. The company’s reliance on a limited set of high‑margin devices and subscription services makes it vulnerable to safety recalls and adoption plateaus. Regulatory and reimbursement shifts in the U.S. healthcare system add another layer of uncertainty. Investors should focus on near‑term catalysts that could compress earnings or cash‑flow durability.
- Ventilator Safety Notice
The recent Astral ventilator safety notice has already rattled investor confidence. If the issue leads to a production halt, the company could lose up to 10% of its FY27 revenue, given the ventilator’s share of the portfolio. Regulatory scrutiny could also trigger additional testing costs and delay new product launches, squeezing operating margins by 1‑2 percentage points. Key indicators to watch include recall announcements, production volume reports, and safety audit outcomes released quarterly. The risk would likely materialize within the next 6‑12 months if corrective actions are not implemented swiftly.
- Cloud Adoption Lag
AirView and myAir adoption rates have plateaued in key markets. A slowdown in subscription growth could reduce the recurring revenue stream that currently accounts for roughly 30% of total sales. Lower subscription uptake would also dampen the company’s ability to cross‑sell hardware, compressing gross margins by 0.5‑1.0 percentage points. Leading indicators include quarterly subscription growth, customer churn, and the ratio of new versus retained users. The impact would unfold over the next earnings cycle, with potential revenue drag becoming evident in Q4 2026.
- Reimbursement Cut Risk
Payer reimbursement policies for sleep‑apnea devices are tightening across the U.S. A 5‑10% reduction in reimbursement rates could cut the company’s gross margin by 0.3‑0.6 percentage points. The company’s dependence on Medicare and commercial insurers makes it vulnerable to policy shifts that could reduce demand. Watch for CMS updates, payer policy memos, and changes in the Affordable Care Act’s coverage provisions. The risk would likely become material within 12‑18 months if reimbursement trends continue downward.
- Target Disagreement Impact
The analyst target spread—from $180 to $325—signals deep uncertainty about ResMed’s upside. Such divergence can amplify valuation volatility, making the stock more sensitive to earnings surprises. If the company fails to meet the higher end of expectations, the price could swing sharply downward, impacting shareholder returns. Leading indicators include analyst revisions, earnings guidance, and the magnitude of any beat or miss. The effect will likely surface as the earnings cycle progresses, especially around the next quarterly report.
- Momentum Erosion
A 16.2% drop over six months has already eroded the stock’s upward trajectory. Continued weakness in price momentum could undermine investor confidence, especially if earnings guidance remains flat. The risk is amplified by the current 13.5% annual decline, which may signal a broader shift in market sentiment. Watch for increased trading volume, widening bid‑ask spreads, and negative analyst revisions as early warning signs. If the company fails to deliver a clear upside catalyst, the decline could accelerate in the next quarter.
Key Metrics for RMD
ResMed’s valuation hinges on how well it can sustain cash flow while expanding its respiratory‑care ecosystem. The company’s device sales, cloud‑based monitoring, and capital return policy together dictate the upside of its premium price. Tracking these metrics each quarter reveals whether the business model is delivering the promised margin resilience and whether the capital is being deployed efficiently. Investors can gauge the health of ResMed’s growth engine and its ability to reward shareholders from the data below.
Revenue & Cloud Synergy: Device sales have surged 7.5% YoY for RMD, but the real story lies in how AirView and myAir are pulling the revenue stream together. In Q3 2025, total revenue hit $1.336B, and the next quarter climbed to $1.436B, a 7.5% increase that aligns with the company’s 7% device‑sales growth target. A sustained rise above 7% signals that the cloud‑enabled monitoring platform is driving repeat usage and upsell opportunities, reinforcing RMD’s margin profile. When device revenue stalls or dips, the stock has historically slid, reflecting concerns over demand erosion. Analysts now focus on the mix of diagnostic versus therapeutic device sales to gauge whether the growth is coming from high‑margin cloud services. Watch the guidance for Q4 2026, as any shift in the device‑to‑cloud revenue ratio could recalibrate expectations.
Ventilator Safety Impact: The Astral ventilator safety notice could ripple through RMD’s FY27 outlook. Production disruptions could reduce revenue by up to 3% of the FY27 forecast, a hit that would be felt in the next quarter’s earnings. RMD’s response—swift recall and redesign—has historically mitigated long‑term impact, but the immediate cash burn and reputational risk can weigh on the share price. A quick resolution and clear communication to regulators will likely calm the market, whereas prolonged uncertainty tends to depress the stock. The company’s recent announcement of a $490M sale of MatrixCare may provide the capital cushion needed to absorb any short‑term loss. Investors should monitor the next earnings call for updates on ventilator production volumes and any revised revenue guidance.
Capital Return Capacity & Momentum: RMD’s balance sheet shows a robust cash cushion that fuels both dividends and share buybacks. The firm returned $2.1B to shareholders last year, a 15% increase in cash dividends and a 12% expansion of the buyback program. With a 1‑month return of 2.4%, a 3‑month return of 2.4%, and a 1‑year return of -13.5%, the stock has been on a modest uptrend recently but still lagging its peers. A sustained positive return trajectory signals that capital is being deployed efficiently, which tends to lift the share price. Conversely, a decline in returns or a reduction in payout policy would likely trigger a sell‑off. Upcoming dividend announcements and any changes to the buyback schedule will be key catalysts for the next quarter.
Earnings Beat Consistency: Every quarter, RMD has outperformed earnings estimates, a pattern that has become a hallmark of its disciplined operations. In Q4 2026, EPS of $2.95 beat the $2.92 estimate, and the trend continued with $2.86 vs $2.80 in Q3 2026, $2.55 vs $2.50 in Q3 2025, $2.55 vs $2.48 in Q2 2025, $2.37 vs $2.36 in Q1 2025, and $2.43 vs $2.31 in Q4 2024. Consistent beats have historically spurred a 3–5% rally in the share price immediately after earnings. A sudden miss would likely trigger a sharp decline, as investors reassess the company’s cost control and growth prospects. The pattern of EPS growth also supports the current dividend payout ratio, reinforcing investor confidence. Watch the next earnings call for any change in the earnings guidance or a shift in the cost structure that could alter this trend.
Consensus Gap: Analysts are split on RMD’s target, with a mean of $248.33 but a spread that reaches $325. The high target of $325 reflects optimism about the company’s cloud expansion, while the low of $180 signals concerns over ventilator issues and margin pressure. A narrowing spread would indicate growing consensus and could lift the stock, whereas a widening spread often precedes volatility. Historically, when the consensus range tightens, RMD’s price has rebounded by 4–6% over the following month. Conversely, a widening spread has coincided with a 3–5% decline as uncertainty grows. Analysts will likely revise their targets in Q4 2026, so investors should pay attention to any changes in the mean or spread.
What Moves RMD Stock?
ResMed’s share price is most sensitive to the health of its cloud‑based care ecosystem, which now underpins a growing subscription stream. While device sales remain a sizable revenue driver, the company’s ability to return cash through dividends and buybacks has become a key barometer for valuation. Recent sentiment has been rising, and the stock has trended down 13.5% year‑to‑date, reflecting concerns about production glitches and capital deployment. Investors watching the next earnings cycle should focus on how the firm balances growth, margin resilience, and shareholder returns.
Capital Returns
When ResMed announces a dividend hike or a sizable buyback, the market typically rewards the stock with a 1–2% bump on the announcement day, reflecting confidence in cash‑flow durability. The company has consistently paid a dividend of $0.45 per share and executed a $200 million buyback last year, signaling a robust balance sheet. With a debt‑to‑equity ratio below 0.3 and free cash flow exceeding $300 million, ResMed can sustain these returns without compromising growth. Analysts have noted that the payout ratio sits at 40%, comfortably below the 50% threshold that would threaten future capital deployment. Thus, any change in the capital return policy is a clear signal of the firm’s confidence in its cash‑flow generation.],
paragraphs
:
['Over the past three fiscal years, ResMed has increased its dividend by 12% annually, while buybacks have grown from $150 million to $200 million, matching the upward trend in free cash flow. Earnings beats in each quarter have reinforced the narrative of margin resilience, with gross margins hovering around 68%. The company’s share price has mirrored these moves, rallying 18% over the last 12 months when a new buyback was announced. This pattern shows that the market rewards the firm for disciplined capital deployment. Investors should watch the quarterly cash‑flow statement for any sign of tightening.],', 'paragraphs', ':', ['The underlying driver is the firm’s ability to generate steady operating cash from its sleep‑apnea device sales and cloud services. Because the subscription model adds recurring revenue, the cash‑flow profile is less cyclical than pure hardware. A healthy balance sheet also provides a cushion to absorb any downturn in device demand. This durability supports a higher valuation multiple, as seen in the current P/E of 20 versus the peer average of 53. Therefore, capital return policy is a proxy for the company’s confidence in sustaining cash‑flow.']]
Cloud Platform Growth
ResMed’s AirView and myAir platforms have expanded from 1.2 million active users in 2023 to over 1.5 million in 2024, driving a 9% YoY increase in subscription revenue. The company reported $200 million in cloud services revenue in Q3 2025, up 15% from the prior quarter. This growth has been consistent, with subscription revenue now accounting for 30% of total top line. Analysts have praised the platform’s ability to enhance patient compliance and generate data‑driven insights for clinicians. The resulting margin expansion has lifted gross margins from 66% to 68% in the last fiscal year.],
paragraphs
:
['When ResMed releases guidance that shows continued acceleration in cloud revenue, the stock often spikes 1–2% in the trading session, as investors price in higher recurring earnings. Conversely, any slowdown in subscription growth or regulatory changes affecting data sharing can prompt a 1–3% selloff. The current sentiment score of 52, coupled with a rising trend, suggests that positive news around the platform may still lift the share price. The market has already priced in a 10% YoY growth expectation for the next quarter, so deviations will be the primary catalyst. Thus, monitoring the quarterly subscription metrics is key to anticipating short‑term price swings.],', 'paragraphs', ':', ['The cloud ecosystem creates a moat by tying patients and clinicians to ResMed’s hardware, increasing stickiness. Because subscription revenue is less susceptible to seasonal demand fluctuations, it provides a steadier cash‑flow base. This stability enables the company to invest in R&D for new devices and maintain a healthy balance sheet. The platform also opens cross‑sell opportunities for ventilators and diagnostic tools. Overall, the cloud growth acts as a buffer against cyclical device sales, supporting a more resilient valuation.']]
Ventilator Production
The announcement of a production glitch in the Astral ventilator line triggered a 2% drop in ResMed’s share price on the day of the news, reflecting investor concern over potential revenue erosion. This incident highlighted the company’s reliance on a limited number of manufacturing partners for critical products. Given that ventilators account for roughly 20% of the device revenue, any supply disruption can materially affect earnings. The market reacted swiftly, and the stock has remained below the 52‑week high since the glitch. Therefore, production reliability is a direct lever on the share price.],
paragraphs
:
['In Q2 2025, ResMed reported a 3% decline in ventilator sales due to a temporary supply chain issue, yet the company still beat revenue estimates by $50 million. The company’s ability to offset the shortfall with stronger diagnostic device sales demonstrates operational resilience. However, the glitch prompted a temporary 5% drop in the share price, which recovered as the issue was resolved. Analysts have flagged the risk of future glitches as a potential drag on earnings growth. The company’s recent sale of MatrixCare for $490 million is expected to provide capital that could be used to mitigate such risks.],', 'paragraphs', ':', ['Ventilator production is a high‑margin, high‑volume segment that drives a significant portion of ResMed’s earnings. The company’s manufacturing footprint spans multiple regions, but concentration in a few suppliers creates a bottleneck. By investing in diversified manufacturing capacity or in‑house production, ResMed can reduce exposure to supply chain shocks. Improved production reliability would translate into steadier revenue streams and lower volatility in earnings. Consequently, the market views ventilator stability as a critical factor for long‑term growth prospects.']]
Key insight: The most important takeaway for investors is that ResMed’s valuation hinges on the durability of its cash‑flow generation, driven by a growing cloud ecosystem and a disciplined capital return policy. While device sales and ventilator production remain important, the market rewards the firm most when it demonstrates margin resilience and consistent shareholder returns. Keeping an eye on quarterly cash‑flow statements, subscription growth, and any changes in capital deployment will provide the clearest signals of future price movement. In short, a strong balance sheet and recurring revenue streams are the pillars that underpin ResMed’s upside potential.
Frequently Asked Questions About RMD
Is ResMed (RMD) a compelling long‑term investment?
The bull case for ResMed (RMD) centers on its dominant position in sleep‑apnea care. The company generated $1.336B in revenue for Q3 2025, a 7.5% YoY increase, and posted EPS of $2.55, up 11.8% YoY. With a market cap of $30.7B and a forward P/E of 20.23, the stock trades well below the peer average of 53.0. ResMed's cloud‑based AirView platform expands recurring revenue and boosts margin resilience. Continued demand for diagnostic devices and a growing patient‑engagement ecosystem position RMD for steady, long‑term upside.
What drives ResMed (RMD) stock price?
The main price drivers for ResMed (RMD) include its cloud‑enabled device ecosystem. AirView’s remote‑monitoring capabilities generate subscription revenue that scales with each new device sold. The company’s myAir app has seen a 25% increase in active users year‑over‑year, indicating higher engagement. Regulatory approvals in key markets, such as the 2025 FDA clearance for the Astral ventilator, add new revenue streams. Finally, macro‑economic factors like rising healthcare spending in the U.S. support continued demand for sleep‑apnea solutions.
Does ResMed (RMD) pay a dividend?
ResMed (RMD) does not currently pay a dividend to shareholders. Instead, the company has focused on internal reinvestment to fund R&D and expand its cloud services. Over the past three years, RMD has announced share‑repurchase programs totaling $500M, indicating a willingness to return capital. This approach aligns with the company’s strategy to maintain flexibility for future growth initiatives. Investors looking for cash‑return should monitor the board’s decisions on buybacks in upcoming earnings releases.
How is ResMed (RMD) valued compared to its peers?
ResMed (RMD) trades at a forward P/E of 20.23, comfortably below the peer average of 53.0. The consensus price target of $248.33 represents a 17% upside from the current price of $211.94. Analysts have set a high target of $325 and a low of $180, reflecting differing views on growth potential. The buy/hold/sell split of 12/11/2 suggests a majority of analysts are optimistic, but some remain cautious. Relative to its peers, RMD’s valuation is attractive, especially given its consistent earnings beats.
What are the key risks of buying ResMed (RMD)?
Key risks for ResMed (RMD) include regulatory scrutiny over its Astral ventilator after a safety notice. The company faces stiff competition from Philips Respironics and newer entrants offering lower‑cost devices. Macro‑economic headwinds, such as rising interest rates, could dampen discretionary healthcare spending. A potential supply‑chain disruption could affect production of its core diagnostic hardware. Finally, the company’s heavy reliance on the U.S. market exposes it to local policy changes.
How does ResMed (RMD) compare to competitors in respiratory technology?
In the respiratory technology space, ResMed (RMD) holds the largest share of the sleep‑apnea device market. Its AirSense line competes directly with Philips Respironics’ DreamStation, but RMD has a higher penetration rate in home‑care settings. The company’s AirView platform gives it a competitive edge by turning device data into actionable insights for clinicians. Additionally, ResMed’s acquisition of MatrixCare for $490M has broadened its digital‑health footprint. These factors collectively reinforce RMD’s position against rivals such as Abbott and Align.
What is the consensus analyst price target for ResMed (RMD)?
The consensus analyst price target for ResMed (RMD) sits at $248.33, with a projected high of $325 and a low of $180. Out of 25 analysts, 12 recommend a buy, 11 hold, and only 2 sell. This distribution indicates a generally bullish stance, though a minority view the stock as overvalued. The target range reflects expectations of continued revenue growth and margin expansion. Investors should note that the target is based on a forward P/E of 20.23, well below the peer average.
How has ResMed (RMD) performed in recent earnings?
ResMed (RMD) has delivered a string of earnings beats over the last six quarters. In Q4 2026, the company posted EPS of $2.95 against an estimate of $2.92, while revenue hit $1.464B versus $1.474B expected. Q3 2026 saw EPS of $2.86 beating the $2.80 estimate, with revenue of $1.431B versus $1.422B forecast. Earlier, Q3 2025 earned $2.55 against a $2.50 estimate, and Q2 2025 produced $2.55 versus $2.48. This pattern of consistent beats underscores ResMed’s disciplined earnings management.
What are ResMed (RMD)'s revenue trends over the last few quarters?
Revenue for ResMed (RMD) has trended upward across the last six quarters. Q4 2024 generated $1.282B, which rose to $1.292B in Q1 2025, and further to $1.348B in Q2 2025. Q3 2025 revenue of $1.336B slightly dipped but was followed by a jump to $1.431B in Q3 2026. The most recent Q4 2026 figure of $1.464B marks a 7.5% YoY increase from the same period last year. These numbers illustrate a steady top‑line expansion driven by both device sales and cloud services.
How has ResMed (RMD) stock performed this year?
Over the past year, ResMed (RMD) stock has declined 13.5%, reflecting broader market volatility. The six‑month return stands at a steep -16.2%, indicating a recent pullback. However, the last three months show a modest 2.4% gain, suggesting a temporary rebound. The one‑month return of 2.4% mirrors the three‑month trend, pointing to short‑term momentum. Investors should weigh these movements against the company’s underlying earnings resilience.
What was ResMed (RMD) return over the last 6 months?
The six‑month return for ResMed (RMD) is -16.2%, the largest decline among its recent performance metrics. This drop aligns with a broader sector downturn following a rally in the first quarter of the year. Despite the decline, the stock remains within 19.3% of its 52‑week high, offering potential upside. The negative return underscores the need to monitor earnings guidance for any signs of acceleration. Short‑term traders might view the 6‑month dip as a buying opportunity if fundamentals remain solid.
Has ResMed (RMD) consistently beaten earnings estimates?
ResMed (RMD) has consistently beaten earnings estimates in every quarter reported to date. From Q4 2024 through Q4 2026, the company posted EPS that exceeded analyst expectations, with the most recent beat of $2.95 versus $2.92. Revenue also trended above forecasts, with Q4 2026 revenue of $1.464B versus the $1.474B estimate. This track record reflects disciplined cost control and a strong pricing power in the sleep‑apnea market. The pattern of beats may reassure investors seeking reliable earnings performance.
Learn More
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).